A Phase 1/Phase 2 Study of Polyvalent Pneumococcal Conjugate Vaccine (V116) in Adults (V116-001)
A Phase 1/Phase 2, Randomized, Double-blind Study to Evaluate the Safety, Tolerability, and Immunogenicity of a Polyvalent Pneumococcal Conjugate Vaccine in Adults.
Sponsor: Merck Sharp & Dohme LLC
Listed as NCT04168190, this PHASE1/PHASE2 trial focuses on Pneumonia, Pneumococcal and remains completed. Sponsored by Merck Sharp & Dohme LLC, it has been updated 17 times since 2019, reflecting substantial change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
17 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE1/PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE1/PHASE2
Phase: PHASE1_PHASE2 → PHASE1/PHASE2
-
Sep 2022 — Jul 2024 [monthly]
Completed PHASE1_PHASE2
-
Jun 2022 — Sep 2022 [monthly]
Completed PHASE1_PHASE2
-
Sep 2021 — Jun 2022 [monthly]
Completed PHASE1_PHASE2
Status: Active Not Recruiting → Completed
▶ Show 12 earlier versions
-
Mar 2021 — Sep 2021 [monthly]
Active Not Recruiting PHASE1_PHASE2
-
Feb 2021 — Mar 2021 [monthly]
Active Not Recruiting PHASE1_PHASE2
Status: Recruiting → Active Not Recruiting
-
Jan 2021 — Feb 2021 [monthly]
Recruiting PHASE1_PHASE2
-
Dec 2020 — Jan 2021 [monthly]
Recruiting PHASE1_PHASE2
-
Nov 2020 — Dec 2020 [monthly]
Recruiting PHASE1_PHASE2
-
Jul 2020 — Nov 2020 [monthly]
Recruiting PHASE1_PHASE2
-
Jun 2020 — Jul 2020 [monthly]
Recruiting PHASE1_PHASE2
-
Apr 2020 — Jun 2020 [monthly]
Recruiting PHASE1_PHASE2
-
Mar 2020 — Apr 2020 [monthly]
Recruiting PHASE1_PHASE2
-
Feb 2020 — Mar 2020 [monthly]
Recruiting PHASE1_PHASE2
-
Jan 2020 — Feb 2020 [monthly]
Recruiting PHASE1_PHASE2
Status: Not Yet Recruiting → Recruiting
-
Dec 2019 — Jan 2020 [monthly]
Not Yet Recruiting PHASE1_PHASE2
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Merck Sharp & Dohme LLC
For direct contact, visit the study record on ClinicalTrials.gov .